Spinal Muscular Atrophy Treatment Access Landscape: Spinraza, Itvisma, & Evrysdi

The therapeutic landscape for spinal muscular atrophy (SMA) is experiencing a decisive second wave of commercial and clinical maturation in 2026. What was historically a fatal neurodegenerative disorder characterized by infant mortality and progressive motor neuron loss has become a multi-billion-dollar rare-disease market anchored by four distinct FDA-approved therapies and an imminent regulatory decision on the first muscle-targeted add-on therapy. Over the past nine months, three transformative events reshaped the SMA treatment paradigm: the November 24, 2025 approval of Itvisma (onasemnogene abeparvovec-brve) as the first intrathecal gene therapy for patients aged 2 and older; the March 27, 2026 approval of the high-dose Spinraza (nusinersen) regimen; and the pending September 30, 2026 PDUFA action date for apitegromab, Scholar Rock's investigational anti-myostatin monoclonal antibody.

For specialty pharmacy executives, health plan medical directors, rare-disease access teams, and pediatric neuromuscular specialists, managing the 2026 SMA formulary requires balancing distinct administration routes, benefit-routing structures (medical vs. pharmacy benefit), gene-therapy pricing models ($2.1 million to $2.59 million one-time list prices), and independent health-technology assessment benchmarks. With oral Evrysdi (risdiplam) solidifying its commercial leadership at over $2 billion in annual revenue and newborn screening (NBS) identifying presymptomatic infants in virtually all 50 U.S. states, the clinical debate has shifted from basic survival toward optimizing functional motor independence in chronic, later-onset populations.

                         [ Spinal Muscular Atrophy Treatment Paradigm (2026) ]
                                                   |
       -----------------------------------------------------------------------------------------
      |                               |                             |                           |
[ 1. SMN2 ASO Modulation ]     [ 2. SMN1 Gene Replacement ]  [ 3. Oral Small Molecule ]  [ 4. Muscle-Directed Add-On ]
- Spinraza (Nusinersen)        - Zolgensma (IV; <2 yrs)      - Evrysdi (Risdiplam)       - Apitegromab (Anti-Myostatin)
- High-Dose Approved Mar 2026  - Itvisma (IT; >=2 yrs)       - Daily Liquid Formulation  - PDUFA: Sep 30, 2026
- Intrathecal (J2326)          - $2.1M (J3399) / $2.59M WAC (C9309)  - Pharmacy Benefit (NDC)    - SAPPHIRE Phase 3 Trial

This dossier provides a comprehensive access guide to the spinal muscular atrophy treatment landscape. Leveraging primary regulatory data from the FDA Orange Book, FDA Purple Book, Drugs@FDA, ClinicalTrials.gov registry records, and Institute for Clinical and Economic Review (ICER) evidence reports, we analyze product positioning, pricing economics, benefit routing, and pipeline timelines.

---

What SMA therapies are FDA-approved in 2026 and who is each one for?

Spinal muscular atrophy is caused by homozygous deletion or loss-of-function mutation in the SMN1 gene, leading to deficiency of survival motor neuron (SMN) protein and irreversible motor neuron degeneration. Phenotypic severity is modulated by the copy number of the centromeric paralog SMN2, which produces mostly truncated, non-functional protein due to alternative splicing of exon 7. Four FDA-approved therapies target this underlying genetic defect through three distinct mechanisms:

                       [ Presymptomatic Newborn or Confirmed 5q SMA ]
                                             |
       -----------------------------------------------------------------------------
      |                                                                             |
[ Age < 2 Years ]                                                          [ Age >= 2 Years ]
- Zolgensma (IV Gene Therapy)                                              - Evrysdi (Oral Daily at Home)
- Spinraza (Intrathecal ASO; Standard/High-Dose)                           - Spinraza High-Dose (Intrathecal q4m)
- Evrysdi (Oral Daily Solution)                                            - Itvisma (Intrathecal Gene Therapy)
                                                                           - Potential Add-On: Apitegromab

Clinical Positioning and Channel Segmentation

1. Infants Under 2 Years (Presymptomatic & Type 1 SMA):
   • First-Line Gene Therapy: Zolgensma remains the dominant choice for newly diagnosed infants identified via universal newborn screening (now active across all 50 states). Over 5,000 infants have been treated globally, providing rapid, single-dose systemic SMN protein restoration.
   • Alternative Chronic Starters: Infants with high baseline anti-AAV9 antibody titers (above 1:50), pre-existing hepatic impairment, or parental preference for chronic therapy are initiated on oral Evrysdi or intrathecal Spinraza.
2. Children Aged 2 and Older, Teens, and Adults (Type 2 & Type 3 SMA):
   • The Oral Leader: Evrysdi has captured market leadership across chronic, older populations due to convenient daily home administration, non-invasive delivery avoiding repetitive lumbar punctures, and systemic tissue distribution. Roche reported more than $2.0 billion in FY2025 run-rate sales with over 16,000 patients treated globally.
   • High-Dose Spinraza: Designed to re-engage older patients with progressive motor decline or severe scoliosis/spinal fusion requiring specialized fluoroscopic lumbar access.
   • Itvisma Intrathecal: Novartis's newly approved intrathecal vector bypasses systemic vascular exposure, allowing older patients (who were previously excluded from Zolgensma due to body-weight toxicity limits) to receive a one-time gene therapy.

---

What changed with the high-dose Spinraza regimen (Mar 27 2026) and intrathecal Itvisma (Nov 24 2025)?

The years 2025 and 2026 brought two major regulatory breakthroughs that dismantled long-standing clinical boundaries in SMA management:

                  [ 2025–2026 Major SMA Regulatory Advances ]
                                       |
    -----------------------------------------------------------------------
   |                                                                       |
[ High-Dose Spinraza (Mar 27, 2026) ]                   [ Itvisma Intrathecal (Nov 24, 2025) ]
- NDA 209531 / SUPPL-016 approval                       - BLA 125856 distinct biological license
- Two 50 mg loading doses (Day 1, 15)                   - One-time lumbar puncture AAV9 vector
- 28 mg maintenance every 4 months                      - Indicated for ages 2 and older (no upper age limit)
- Substantially higher CSF drug exposure                 - Overcomes IV weight-based liver toxicity ceiling

High-Dose Spinraza: The 50 mg / 28 mg Regimen

On March 27, 2026, the FDA approved Biogen's supplemental New Drug Application (NDA 209531 / SUPPL-016) for a new higher-dose nusinersen regimen, following European Commission approval in January 2026.

• Dosing Architecture:
  • Treatment-Naïve Patients: Initiated with two loading doses of 50 mg administered 14 days apart (Day 1 and Day 15), followed by 28 mg maintenance doses every 4 months.
  • Switching from Standard 12 mg: Patients currently on standard Spinraza transition via a single 50 mg loading dose, followed by 28 mg every 4 months.
• Pivotal Evidence (DEVOTE Trial): Published by Finkel et al. in Nature Medicine (2026;32(3):1095-1104; doi: 10.1038/s41591-025-04193-6), the three-part Phase 2/3 DEVOTE study (NCT04089566) enrolled 145 patients. In the pivotal cohort, treatment-naïve symptomatic infants on the high-dose regimen achieved statistically significant CHOP-INTEND improvements versus a prespecified matched sham control from the ENDEAR study (mean difference 26.19 points), delivering substantially higher CSF nusinersen exposure than the 12 mg regimen, with a safety profile consistent with the established Spinraza label.
• Formulary Impact: High-dose Spinraza establishes new Orange Book exclusivity (NS exclusivity to March 27, 2029) and allows Biogen to defend its market share against oral risdiplam (Spinraza posted $1.55 billion in global 2025 sales, essentially flat versus 2024).

Itvisma: Intrathecal Gene Replacement for Older Populations

On November 24, 2025, the FDA approved Itvisma (onasemnogene abeparvovec-brve, BLA 125856) as a one-time intrathecal gene therapy for pediatric (aged 2 and older), adolescent, and adult patients with confirmed SMN1 mutations.

• The Clinical Bottleneck It Resolved: Intravenous Zolgensma carries a strict label limitation to patients under 2 years of age, largely because systemic IV administration in heavier children and adults requires massive total viral loads that trigger life-threatening acute liver failure, thrombotic microangiopathy (TMA), and systemic immune activation.
• Targeted Intrathecal Delivery: Direct lumbar intrathecal injection delivers the functional SMN1 transgene directly into the CSF, achieving dense transduction of spinal motor neurons with a fraction of the systemic viral exposure.
• Commercial Scope: Novartis estimates that of the roughly 9,000 individuals living with SMA in the United States, the overwhelming majority are aged 2 and older. Itvisma opens the adult and adolescent prevalent population to one-time gene replacement therapy.
• Boxed Warning & Safety: Itvisma carries a Boxed Warning for hepatotoxicity, requiring baseline liver function testing, troponin-I monitoring, platelet counts, and mandatory systemic corticosteroid prophylaxis starting the day before injection per FDA-approved labeling.

---

What does each therapy cost and through which benefit does it flow?

The financial management of spinal muscular atrophy involves severe structural divergence between high-cost upfront medical claims and ongoing chronic pharmacy spend:

                            [ SMA Benefit Routing Architecture ]
                                              |
      ---------------------------------------------------------------------------------
     |                                                                                 |
[ Medical Benefit (Buy-and-Bill / J-Codes) ]                        [ Pharmacy Benefit (NDC Specialty) ]
- Spinraza: HCPCS J2326 ($125k/dose; ~$375k/yr)                     - Evrysdi: Daily oral liquid
- Zolgensma: HCPCS J3399 ($2.10M one-time WAC)                      - Annualized Cost: $340k–$400k (weight-based)
- Itvisma: HCPCS C9309 ($2.59M one-time WAC)                        - Home specialty pharmacy delivery

Channel Insights from CMS Datasets

• CMS NADAC Absence: Similar to other rare-disease therapies, nusinersen, onasemnogene, and risdiplam are entirely absent from the CMS National Average Drug Acquisition Cost (NADAC) dataset. None of these products flow through the surveyed retail community pharmacy supply chain.
• Distribution Channels: Evrysdi is dispensed exclusively through limited-distribution specialty pharmacies (such as Accredo, CVS Specialty, and Optum Specialty) with dedicated cold-chain home delivery. Spinraza, Zolgensma, and Itvisma are purchased through specialized hospital buy-and-bill or white-bagged through certified treatment centers.

---

What is apitegromab, why did its first BLA get a CRL, and what happens at the Sep 30 2026 PDUFA?

While existing SMA therapies increase functional SMN protein levels to halt motor neuron loss, they do not directly repair downstream skeletal muscle atrophy or contractures. Apitegromab (SRK-015), developed by Scholar Rock, is an investigational human monoclonal antibody that selectively inhibits the activation of pro-myostatin and latent myostatin, preventing the release of mature active myostatin in skeletal muscle.

                      [ Upstream SMN Therapy vs Downstream Muscle Therapy ]
                                                |
       -----------------------------------------------------------------------------------
      |                                                                                   |
[ SMN-Upregulating Therapy (Base) ]                                 [ Apitegromab Add-On (Muscle) ]
- Spinraza, Evrysdi, Zolgensma, Itvisma                             - Selective anti-pro/latent myostatin mAb
- Halts motor neuron apoptosis & loss                               - Inhibits muscle wasting & promotes hypertrophy
- Preserves neuromuscular junction integrity                        - Improves functional motor scores (HFMSE)

Pivotal Clinical Evidence: The SAPPHIRE Trial

Apitegromab is designed as an add-on therapy for patients with Type 2 and Type 3 SMA who are already receiving background SMN-targeted therapy (nusinersen or risdiplam).

• Trial Design (NCT05156320): The Phase 3 SAPPHIRE study enrolled 188 non-ambulatory patients aged 2 to 21 years with Type 2 or Type 3 SMA on stable background nusinersen or risdiplam. Patients aged 2 to 12 (the main efficacy population) were randomized 1:1:1 to apitegromab 10 mg/kg, apitegromab 20 mg/kg, or placebo every four weeks; patients aged 13 to 21 were randomized 2:1 to the 20 mg/kg dose or placebo.
• Efficacy Results: Published in The Lancet Neurology, the trial met its primary endpoint. In the main efficacy population, patients receiving apitegromab (combined doses, n=106) demonstrated a mean improvement of 1.8 points on the Hammersmith Functional Motor Scale Expanded (HFMSE) versus placebo (n=50) at 12 months (p = 0.0192), while placebo-group motor scores declined; the 13-to-21 population showed the same 1.8-point mean difference.
• Designations: FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations (qualifying for a Priority Review Voucher upon approval), alongside EMA PRIME status.

The September 2025 CRL: A Textbook Facility Observation

On September 22, 2025, the FDA issued a Complete Response Letter (CRL) regarding the initial apitegromab BLA. Crucially:

• Zero Clinical or Efficacy Deficiencies: The CRL cited no concerns regarding clinical safety, efficacy, dosing, or trial integrity.
• Third-Party Fill-Finish Facility Inspection: The CRL was issued solely due to inspectional observations (Form FDA 483 citations) at a third-party contract manufacturing organization (CMO) fill-finish site—specifically the Catalent facility in Bloomington, Indiana (now Novo Nordisk).
• Resolution & Resubmission: Scholar Rock resubmitted the BLA with an expanded chemistry, manufacturing, and controls (CMC) module that qualified an additional, fully inspected secondary U.S. fill-finish facility. The FDA formally accepted the resubmission, establishing a class 2 review timeline with a PDUFA action date of September 30, 2026.

For a broader evaluation of regulatory non-approval mechanics, see our FDA complete response letter guide.

---

How did ICER price SMA therapies and what should payers do with the 8-5 uncertainty vote?

In September 2025, the Institute for Clinical and Economic Review (ICER) released its comprehensive Final Evidence Report on treatments for spinal muscular atrophy. The report evaluated the cost-effectiveness and comparative clinical effectiveness of apitegromab as an add-on therapy, producing critical benchmarks for commercial payers:

                            [ ICER SMA Evidence Evaluation (2025) ]
                                              |
      ---------------------------------------------------------------------------------
     |                                                                                 |
[ Midwest CEPAC Voting Outcome ]                                    [ Health-Benefit Price Benchmark ]
- 8 to 5 Vote: Evidence INADEQUATE                                  - $4,600 to $30,200 per year
  to demonstrate net health benefit                                   (excluding background SMN therapy costs)
- Concerns: 1.8-point HFMSE modest vs cost                           - Assumed Analysis Price: $350,000 / yr
- High background spending ($375k/yr)                               - Cost per evLY: >$2.8 million

The 8–5 Panel Vote on Net Health Benefit

The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) convened by ICER voted 8 to 5 that the current evidence is NOT adequate to demonstrate that apitegromab added to background standard-of-care SMN therapy provides a net health benefit over SMN therapy alone:

• Majority Rationale (8 votes): Panelists cited the relatively modest magnitude of motor score improvement (mean 1.8-point HFMSE separation), uncertainty regarding long-term functional plateau, and the lack of demonstrated durable improvements in activities of daily living (ADL) scales.
• Minority Rationale (5 votes): Pointed to the statistical significance in a homogeneous Phase 3 population, the clean safety profile across more than four years of Phase 2 TOPAZ open-label extension data, and the urgent unmet need for restorative therapies in chronic contractured patients.

Health-Benefit Price Benchmark (HBPB) Calculations

ICER's cost-effectiveness modeling revealed extreme financial tension when adding a new branded biologic on top of an already high-cost chronic baseline:

• Baseline Cost Context: Patients receiving background nusinersen or risdiplam already incur $340,000 to $375,000 in annual drug spending.
• Assumed Analysis Price: ICER utilized a placeholder price of $350,000 per year for apitegromab.
• Incremental Cost-Effectiveness Ratio (ICER): At $350,000/year, apitegromab generated an incremental cost-effectiveness ratio exceeding $2.8 million per equal-value life-year (evLY) gained—far above conventional willingness-to-pay thresholds ($100,000 to $150,000 per evLY).
• Calculated Health-Benefit Price Benchmark:
  • To meet the $100,000 to $150,000 per evLY threshold, apitegromab would need to be priced between $4,600 and $30,200 per year (when evaluated independently of background therapy costs).
• Budget Impact Threshold: At the $350,000 placeholder price, ICER estimated that only 64% of eligible SMA patients could be treated over five years without exceeding its potential budget-impact threshold.

Payer Strategies Ahead of the September 30 Decision

P&T committees are developing strict utilization gates based on ICER's findings:

1. Mandatory Documentation of Stable Background Therapy: Limiting coverage to patients on documented, adherent nusinersen or risdiplam for at least 6 to 12 months without acute motor decline.
2. Baseline and Renewal Motor Metrics: Requiring baseline physical therapist-administered HFMSE or Expanded Hammersmith testing, with renewal gated behind documented stabilization or improvement (a 2-point-or-greater gain) at 12 months.
3. Outcomes-Based Contracting: PBMs are demanding value-based rebate agreements where manufacturers rebate a significant portion of drug costs if patients fail to achieve predetermined motor milestones.

For insights into CMS value-based contracting for cell and gene therapies, consult our Casgevy CMS CGT model guide.

---

What do Orange Book patents, exclusivities, and next-generation ASO trials show for the SMA horizon?

The long-term competitive landscape for SMA is governed by robust patent portfolios and next-generation clinical development:

                            [ SMA Patent & Pipeline Runway ]
                                           |
      -----------------------------------------------------------------------------
     |                                                                             |
[ Orange Book Patent Horizons ]                                     [ Next-Gen ASO Clinical Pipeline ]
- Spinraza (NDA 209531): 34 Patent Listings                        - Salanersen (BIIB115; Biogen/Ionis)
  (Latest Expiry Mar 4, 2036)
- Evrysdi (NDA 213535): 7 Patents (Latest Apr 15, 2041)             - Phase 3 NCT07444476 (Ages 15–60)
- Evrysdi (NDA 219285): Exclusivity to May 27, 2029                 - Phase 3 NCT07221669 (Presymptomatic)
                                                                    - Phase 3 NCT07444450 (Post-Zolgensma)

Orange Book Patent and Exclusivity Analysis

Empirical inspection of the FDA Orange Book (snapshot July 25, 2026) demonstrates that branded monopolies in SMA will remain unchallenged by generic small molecules or generic oligonucleotides through the mid-2030s:

ClinicalTrials.gov Analysis: The Next-Generation ASO Frontier

Analysis of the ClinicalTrials.gov registry (July 2026 mirror) identifies nine ongoing clinical investigations shaping the future of SMA, led by salanersen (BIIB115), the next-generation ASO developed by Biogen and Ionis:

• Extended Half-Life: Salanersen is engineered for higher target affinity and prolonged intracellular stability, with the potential for intrathecal dosing intervals longer than Spinraza's every-4-month schedule.
• Phase 3 Registrational Program:
  1. NCT07444476: Evaluating motor function in participants aged 15 to 60 years who are treatment-naïve or previously treated with risdiplam.
  2. NCT07221669: Evaluating efficacy in presymptomatic infants with genetically diagnosed SMA.
  3. NCT07444450: Evaluating safety and efficacy in infants previously treated with onasemnogene abeparvovec (Zolgensma) who experience residual weakness.

For related analyses across neuromuscular disease, review our Duchenne muscular dystrophy access landscape, the genome editing clinical trials registry analysis, and the Novartis portfolio dossier.

---

Frequently Asked Questions (FAQ)

When is the FDA decision date for apitegromab?

The FDA accepted Scholar Rock's resubmitted Biologics License Application (BLA) for apitegromab with a PDUFA target action date of September 30, 2026. The review follows the resolution of third-party fill-finish inspection observations cited in a September 2025 Complete Response Letter.

Is Itvisma the same drug as Zolgensma?

Both Zolgensma and Itvisma utilize an adeno-associated virus serotype 9 (AAV9) vector to deliver a functional copy of the human SMN1 gene. However, they hold separate FDA Biologics License Applications (Zolgensma BLA 125694; Itvisma BLA 125856) and different clinical indications: Zolgensma is administered as an intravenous infusion in infants under 2 years of age, whereas Itvisma is administered as a single-dose lumbar intrathecal injection in children aged 2 and older, adolescents, and adults.

What does high-dose Spinraza change for existing patients?

The high-dose Spinraza regimen, approved on March 27, 2026, increases the maintenance dose from 12 mg to 28 mg administered every 4 months, following higher-dose loading (50 mg). Patients transitioning from standard Spinraza receive a single 50 mg loading dose (at least four months after their last 12 mg maintenance dose) before moving to 28 mg maintenance, delivering substantially higher drug concentrations in the cerebrospinal fluid.

How much do spinal muscular atrophy therapies cost annually?

One-time gene therapies carry list prices of $2.1 million (Zolgensma) and $2.59 million (Itvisma). Chronic therapies range from $340,000 to $400,000 annually for oral Evrysdi (dosed daily) and $375,000 annually for standard-dose Spinraza maintenance (about $456,000 on the new high-dose regimen), administered by intrathecal injection three times per year.

---

Sources

1. U.S. Food and Drug Administration (FDA): FDA Approves High-Dose Regimen of SPINRAZA (nusinersen) for Spinal Muscular Atrophy. Drugs@FDA Database (NDA 209531 / SUPPL-016, Mar 27, 2026). Available at: https://www.accessdata.fda.gov/scripts/cder/daf/
2. Novartis Pharmaceuticals: Novartis Receives FDA Approval for Itvisma, the Only Gene Replacement Therapy for Children Aged Two Years and Older, Teens, and Adults with Spinal Muscular Atrophy. Press Release (Nov 24, 2025). Available at: https://www.novartis.com/
3. Scholar Rock Holding Corporation: Scholar Rock Reports First Quarter 2026 Financial Results and Highlights BLA Acceptance for Apitegromab with PDUFA Date of September 30, 2026. Form 10-Q Disclosure & Press Release. Available at: https://investors.scholarrock.com/
4. Institute for Clinical and Economic Review (ICER): Treatments for Spinal Muscular Atrophy: Effectiveness and Value. Final Evidence Report and Report-at-a-Glance (Sep 2, 2025). Available at: https://icer.org/
5. FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): Patent and Exclusivity Data for Nusinersen (NDA 209531) and Risdiplam (NDA 213535, NDA 219285) (Data current through July 2026). Available at: https://www.accessdata.fda.gov/scripts/cder/ob/
6. FDA Database of Licensed Biological Products (Purple Book): Listings for Onasemnogene Abeparvovec-xioi (BLA 125694) and Onasemnogene Abeparvovec-brve (BLA 125856). Available at: https://purplebooksearch.fda.gov/
7. ClinicalTrials.gov: Registrational Studies for Apitegromab (NCT05156320, NCT05626855) and Salanersen (NCT07444476, NCT07221669, NCT07444450). U.S. National Library of Medicine. Available at: https://clinicaltrials.gov/
8. Finkel RS, et al.: High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial (DEVOTE). Nature Medicine. 2026;32(3):1095-1104; doi:10.1038/s41591-025-04193-6.
9. Reuters: Biogen gets FDA approval for higher dose of genetic disorder drug (high-dose vial pricing: 28 mg ~$152,000; 50 mg ~$271,000; FY2025 Spinraza sales $1.55 billion). Mar 30, 2026. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-higher-dose-biogens-genetic-disorder-drug-2026-03-30
10. Aetna Clinical Policy Bulletin 0953: Onasemnogene Abeparvovec (Zolgensma and Itvisma) — HCPCS J3399 (onasemnogene abeparvovec-xioi) and C9309 (onasemnogene abeparvovec-brve) coding. Available at: https://www.aetna.com/cpb/medical/data/900_999/0953.html